Pazopanib in Patients with Osteosarcoma Metastatic to the Lung: Phase 2 Study Results and the Lessons for Tumor Measurement

Table 2

Best overall response.

Primary analysis group
SD > 4 months	4
PD	3
N/A	1 (toxicity)
Subgroup of patients with low tumor growth rate
PR	1
SD > 4 months	1
PD	1
N/A	1